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Supplemented very
low-protein diet in advanced
CRF: Is it money saving?
To the Editor: Based on data gained in a large co-
hort of patients on regular predialysis nephrologic care,
the proportion of subjects with hemoglobin (Hb) level
<11 g/dL, at a creatinine clearance level ≤20 mL/min/
1.73 m2, may be estimated at 60% [1]. Accordingly, two
thirds of predialysis patients should require erythropoi-
etin (EPO) treatment. The high cost of such therapy, how-
ever, remains a major limiting factor for its larger use.
We monitored EPO requirement in a group of patients
with advanced chronic renal failure (CRF) (creatinine
clearance ≤25 mL/min) across a two-year time period
[2]. At the start, patients were divided in a group treated
with very low-protein diet (VLPD, N = 10) (0.3 g/kg
body wt/day of protein of vegetable origin) supple-
mented by ketoanalogs and essential amino acids (Alfa
Kappa, Kedrion, Lucca, Italy administered at the dose
of 1 tablet/5 kg body wt/day) and another group on
usual low-protein diet (LPD, N = 10) (0.6 g of pro-
tein/kg body wt/day) groups did not differ in caloric in-
take (35 kcal/kg body wt/day), gender, age, body mass
index, renal disease, systolic and diastolic blood pres-
sure, and creatinine clearance. Hb levels were main-
tained within the target values in all patients during
the study period (VLPD, Hb = 11.5 ± 0.2 g/dL; LPD,
Hb = 11.5 ± 0.3 g/dL, P = NS). The main result of the
study was that the effective decrease of dietary protein
intake by 0.3 g/kg body wt/day allowed a reduction of
about 35% of the EPO dose required to maintain the tar-
get Hb level in advanced CRF. In addition, the decline of
renal function was reduced in VLPD (0.01 ± 0.22 mL/
min/month) with respect to LPD (−0.30 ± 0.16 mL/
min/month, P < 0.003). As a consequence, during the
24 months of follow-up, 2 VLPD patients and 7 LPD pa-
tients started chronic dialysis treatment.
We have now calculated the costs of therapy provided
in the two groups during the 2 years of observation
(Table 1). VLPD allowed a saving of economic resources
that can be quantified in almost €52,000 (cost in Euros)
for 10 patients during the study, which is a mean of
€2,600/pt/year for each patient with advanced CRF start-
ing a supplemented VLPD for the sole cost of therapy
during two years of treatment. These data remain to
be better defined in a larger population; however, it is
reasonable to suggest that prescription of supplemented
VLPD not only leads to amelioration of the main CRF-
related metabolic disturbances, but also allows a signifi-
cant saving of economic resources.
Table 1. Cost analysis of two years of treatment in CRF patients kept
at either very low-protein diet (VLPD) or low-protein diet (LPD)
VLPD LPD
(N = 10) (N = 10) Difference
Hypoproteic food 5110 4600 510
Alfa-kappa 54,987 0 54,987
Phospate binders 650 2184 −1534
Erythropoietin 68,081 109,196 −41,115
Iron 1642 791 851
Dialysis 16,527 81,972 65,445
Total 146,997 198,743 51,746
Data are in euros.
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Patients developing anti-Epo
antibodies during rHuEpo
treatment do not express a
polymorphic variant of Epo
To the Editor: During the last few years, around 140
patients have developed pure red cell aplasia (PRCA)
during treatment with recombinant human erythropoi-
etin (rHuEpo). In most cases, PRCA was caused by the
production of neutralizing anti-EPO antibodies [1]. Al-
though antibody production was linked to the use of a
specific brand of rHuEpo, the reasons leading to antibody
production are not completely understood, and only a low
percentage of patients treated with this type of rHuEpo
develop antibodies, suggesting that they could have some
characteristics increasing their sensitivity to small modi-
fications of EPO. An attracting possibility would be that
these patients present a polymorphism in the coding re-
gion of the EPO gene. To test this hypothesis, we se-
quenced the coding region of the EPO gene in 9 patients
